Compare Twist Bioscience Corp (TWST) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Twist Bioscience Corp trades at $152.84 (market cap $10.08B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.43 (market cap $296.92M). The key difference: Twist Bioscience Corp is far larger — about 33.9× YieldMax Magnificent 7 Fund of Option Income ETFs's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and YieldMax Magnificent 7 Fund of Option Income ETFs for 62 Days on average.
| TWST | YMAG | |
|---|---|---|
Market Cap | $10.08B | $296.92M |
Volume | 4,229,037 | 1,023,545 |
Sector | Health | Income / Options Overlay |
52-Week High | $205.00 | $15.68 |
52-Week Low | $25.45 | $10.76 |
Typical Hold Time | 27 Days | 62 Days |
Enterprise Value | $10.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
YMAG trades at $11.49, down 0.69% with a bullish technical signal supported by moving averages. The ETF maintains consistent weekly dividend distributions, though key valuation ratios remain unavailable. Recent news highlights ongoing distribution announcements and trading activity, with the stock showing moderate volatility within a tight $11-12 range.
The outlook remains cautiously optimistic given the bullish technical setup and income generation through dividends. However, risks include NAV stability concerns during earnings periods and dependency on underlying option strategies. Investors should weigh the high distribution yield against potential capital volatility in market downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
